Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

14.50
+1.6212.58%
Post-market: 14.870.3700+2.55%19:59 EDT
Volume:12.43M
Turnover:174.90M
Market Cap:1.43B
PE:-2.49
High:14.58
Open:13.22
Low:13.20
Close:12.88
52wk High:39.89
52wk Low:12.73
Shares:98.32M
Float Shares:80.72M
Volume Ratio:2.64
T/O Rate:15.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-4.90
PE(LYR):-2.49

Loading ...

Ultragenyx downgraded to Market Perform from Outperform at William Blair

TIPRANKS
·
Sep 03

William Blair downgrades Ultragenyx Pharmaceutical (RARE) to a Hold

TIPRANKS
·
Sep 03

Ultragenyx Says Phase 3 Study on Rare Neurogenetic Disorder Missed Primary, Secondary Endpoints; Shares Fall After-Hours

MT Newswires Live
·
Sep 03

Ultragenyx Pharmaceutical to Cut Costs After Drug Trial Misses Endpoints

Dow Jones
·
Sep 03

Ultragenyx's Rare Disease Drug Fails in Late-Stage Trial

Reuters
·
Sep 03

Ultragenyx Announces Phase 3 Aspire Results in Angelman Syndrome

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical - Safety Profile in Aspire Study Consistent with Phase 1/2

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical - to Evaluate Apazunersen Program and Implement Significant Expense Reductions

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical - Expects to Continue Toward Profitability in 2027

THOMSON REUTERS
·
Sep 03

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

GlobeNewswire
·
Sep 03

Ultragenyx Unit Amlogenyx Presents at Wells Fargo Healthcare Conference Sept. 8

Reuters
·
Sep 02

Ultragenyx announces publication of Phase 3 Genglycos trial results

TIPRANKS
·
Sep 02

Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of Genglycos™ (Also Known as Dtx401) Aav Gene Therapy in Gsdia in the Journal of Inherited Metabolic Disease

THOMSON REUTERS
·
Sep 02

Ultragenyx Grants 45,984 Inducement RSUs to 23 New Hires

Reuters
·
Aug 26

Ultragenyx Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 26

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 26

Ultragenyx Pharma Price Target Raised to $80.00/Share from $75.00 by JP Morgan

Dow Jones
·
Aug 25

Ultragenyx Pharmaceutical Inc. : Morgan Stanley Raises Target Price to $74 from $67

THOMSON REUTERS
·
Aug 21

Analysts’ Top Healthcare Picks: Evaxion Biotech (EVAX), Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Aug 21

U.S. Stocks on the MOVE-Apple, Hims & Hers Health, Sysco

Reuters
·
Aug 20